{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:28:19Z","timestamp":1777930099534,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Im Rahmen zweier klinischer Phase-II- bzw. -III-Studien wurden Patien-ten mit einem histologisch gesicherten metastasierendem Nierenkarzinom entweder mit \u03b3-Interferon in zwei unterschiedlichen Dosierungen (100 \u03bcg\/m2 3 \u00d7 pro Woche \u00fcber 4 h i.v. jede 2. Woche, oder 500 \u03bcg\/m2, 5 \u00d7 pro Woche \u00fcber 24 h i.v. jede 2. Woche) oder mit \u03b1-2-Interferon allein (18 \u00d7 106 E 3 \u00d7 pro Woche, jede Woche i.m.) oder in Kombination mit Vinblastin (0,1 mg\/kg K\u00f6rpergewicht i.v. jede 3. Woche) behandelt. Ziel dieser Studie war es, die Ansprechrate, die Ansprechdauer, die \u00dcberlebensrate, die Toxizit\u00e4t sowie die Vertr\u00e4glichkeit beider Therapie-formen zu eruieren. Die Ansprechrate lag in der \u03b3-Interferonstudie be\u00ed beiden Dosierungen insgesamt bei 30%, in der Studie mit \u03b1-Interferon in Kombination mit Vinblastin bei insgesamt 31%. Die Ansprechdauer lag in der \u03b3-Interferon-Studie bei 2\u201334+Monaten, bei der \u03b1-2-Interferon-Studie bei 2\u201324 + Monaten. Patienten, die unter der \u03b3-Interferon-Therapie eine Tumorreaktion auf-wiesen, \u00fcberlebten statistisch signifikant l\u00e4nger als diejenigen, die nicht auf die Therapie ansprachen (p = 0,0056). Die Behandlung mit der nie-drigen Dosis des \u03b3-Interferon sowie mit \u03b1-2-Interferon war ambulant gut durchf\u00fchrbar. Die Interferon-Therapie stellt u. E. derzeit bei Patienten mit einem metastasierenden Nierenkarzinom die Therapie der Wahl dar.<\/jats:p>","DOI":"10.1159\/000216519","type":"journal-article","created":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T08:49:09Z","timestamp":1240822149000},"page":"185-191","source":"Crossref","is-referenced-by-count":9,"title":["Die Behandlung des metastasierenden Nierenkarzinoms mit rekombinantem \u03b1-2- oder \u03b3 -Interferon"],"prefix":"10.1159","author":[{"given":"U.","family":"Otto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Denkhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,27]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/216519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000216519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:03:48Z","timestamp":1777680228000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000216519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,27]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000216519","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,27]]}}}